Amphastar has reported its “strongest quarter yet”, as competitor shortages led to outsized sales performances for glucagon while growth trends continued for epinephrine and Primatene Mist, which maintained solid market shares.
Jack Zhang, Amphastar's president and CEO, said: “Looking ahead to 2023, we anticipate launching multiple new products to continue driving...







